MRUS - Merus BV - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MRUS is currently covered by 12 analysts with an average price target of $73.61. This is a potential upside of $31.2 (73.57%) from yesterday's end of day stock price of $42.41.

Merus BV's activity chart (see below) currently has 74 price targets and 110 ratings on display. The stock rating distribution of MRUS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 47.17% with an average time for these price targets to be met of 294.6 days.

Highest price target for MRUS is $111, Lowest price target is $67, average price target is $90.

Most recent stock forecast was given by AMI FADIA from NEEDHAM on 08-Apr-2025. First documented stock forecast 12-Jun-2016.

Currently out of the existing stock ratings of MRUS, 55 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$83

$42.1 (102.93%)

$83

1 months 4 days ago
(08-Apr-2025)

14/26 (53.85%)

$43.44 (109.81%)

328

Buy

$109

$68.1 (166.50%)

$109

1 months 15 days ago
(27-Mar-2025)

1/4 (25%)

$64.39 (144.34%)

650

Buy

$70

$29.1 (71.15%)

$76

2 months 3 days ago
(09-Mar-2025)

0/5 (0%)

$23.25 (49.73%)

Buy

$85

$44.1 (107.82%)

$85

2 months 10 days ago
(02-Mar-2025)

6/13 (46.15%)

$39.53 (86.94%)

286

Buy

$111

$70.1 (171.39%)

$93

7 months 12 days ago
(30-Sep-2024)

0/2 (0%)

$60.9 (121.56%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MRUS (Merus BV) average time for price targets to be met?

On average it took 294.6 days on average for the stock forecasts to be realized with a an average price target met ratio 47.17

Which analyst has the current highest performing score on MRUS (Merus BV) with a proven track record?

BRADLEY CANINO

Which analyst has the most public recommendations on MRUS (Merus BV)?

Bradley Canino works at STIFEL and has 18 price targets and 10 ratings on MRUS

Which analyst is the currently most bullish on MRUS (Merus BV)?

Michael Schmitz with highest potential upside - $70.1

Which analyst is the currently most reserved on MRUS (Merus BV)?

David Nierengarten with lowest potential downside - -$22.11

Merus BV in the News

Merus gibt Finanzergebnisse für das erste Quartal 2025 bekannt und informiert über den aktuellen Geschäftsverlauf

– Phase-II-Studie mit Petosemtamab in Kombination mit Pembrolizumab in der Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierenden Kopf-Hals-Plattenepithelkarzinoms läuft, Aktualisierung der klinischen Daten auf der ASCO®-Jahrestagung 2025 – Basierend auf dem aktuellen Geschäftsplan des Unternehmens, den vorhandenen Barmitteln, Barmitteläquivalenten und handelbaren Wertpapieren wird erwartet, dass die Geschäftstätigkeit von Merus bis ins Jahr 2028 finanziert werden kann UTRECHT, Niederlande,...

Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Merus N.V. (NASDAQ:MRUS) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology Market...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?